Alumis Inc. (ALMS) Stock Analysis
Is ALMS a good investment?
Alumis Inc. (ALMS) has a Plutrex AI rating of 28.5/100 as of November 12, 2026, indicating a Strong Sell consensus. The stock is not classified as halal-compliant. Key strength: Debt-free balance sheet with D/E of 0.07 (vs. industry 0.24) eliminates leverage-induced insolvency; $502.3M cash provides ~17 months of operational runway, buying time for clinical catalysts. Main concern: Phase 2b lupus trial failure ('Alumis Lupus Trial Misses Main Goals') is UNCHANGED — the primary pipeline catalyst is collapsed, the company pivots to a narrower subgroup with uncertain probability of success, extending cash burn trajectory at -$351.8M/year against ~17 months remaining runway; dilutive financing is near-certain.
Investment Summary
ALMS (Alumis) remains a deeply distressed clinical-stage biotech with no material change from the prior report 14 days ago. The stock has drifted further from $7.13 to $6.62 (-7.2%), confirming ongoing selling pressure. The company's core problem is unchanged: a catastrophic operating margin of -5,744.5% (vs. industry average of +5.4%), net margin of -5,933.4% (vs. industry average of -0.86%), revenue contraction of -37.7% YoY (vs. industry growth of +211.1%), and a cash burn of -$351.8M annually against a $502.3M cash balance — yielding approximately 17 months of runway. The defining news event remains the Phase 2b LUMUS lupus trial failure ('Alumis Lupus Trial Misses Main Goals'), which collapsed the company's primary near-term pipeline catalyst. The 58% single-day decline following that announcement reflected rational market re-pricing. While the company is 'eyeing a late-stage lupus study despite trial miss' and presenting positive Phase 3 psoriasis data for envudeucitinib, neither development changes the fundamental trajectory: a company burning $351.8M/year with contracting revenues and a failed mid-stage trial must now carry a heavier burden on a single remaining commercial catalyst. Analyst consensus target of $26.60 is unchanged and remains heroic given execution risk. P/B of 1.88x is the only calculable valuation metric. No P/E or PEG available. This is a lottery ticket, not an investment.
Key Strengths
- Debt-free balance sheet with D/E of 0.07 (vs. industry 0.24) eliminates leverage-induced insolvency; $502.3M cash provides ~17 months of operational runway, buying time for clinical catalysts
- Phase 3 psoriasis data for envudeucitinib ('Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably...') — the only surviving commercial catalyst in a large, growing dermatology market; gross margin of 52.3% confirms product-level unit economics are viable at scale
- High-interferon subgroup signal from LUMUS trial ('Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise') keeps a narrower lupus path alive, and the company is considering a focused late-stage study ('Alumis eyes late-stage lupus study despite trial miss') — preserving some optionality value
Key Concerns
- Phase 2b lupus trial failure ('Alumis Lupus Trial Misses Main Goals') is UNCHANGED — the primary pipeline catalyst is collapsed, the company pivots to a narrower subgroup with uncertain probability of success, extending cash burn trajectory at -$351.8M/year against ~17 months remaining runway; dilutive financing is near-certain
- Revenue contraction of -37.7% YoY (vs. industry growth of +211.1%), operating margin of -5,744.5% (vs. industry +5.4%), and forward EPS growth 67.9% below industry average collectively make ALMS a bottom-tier laggard with no near-term path to profitability — the company must carry the entire commercial burden on unapproved psoriasis therapy
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ALMS's fundamentals are uniformly poor outside of balance sheet structure. Gross margin of 52.3% is the sole product-level positive — it confirms pricing power exists IF revenue scales — but it is 27.6 percentage points below the biotech industry average of 79.86%, signaling weaker differentiation than peers. Operating margin of -5,744.5% (vs. industry +5.4%) and net margin of -5,933.4% (vs. industry -0.86%) are extreme outliers even among loss-making biotechs. These margins reflect a company where operating expenses are approximately 58x revenues — not a temporary scale problem but a fundamental imbalance. ROE of -93.7% vs. industry average of -2.18% confirms equity erosion is 4,194% more severe than peers. Revenue growth of -37.7% YoY vs. industry average of +211.1% — a 248.8 percentage point deficit — means the company is contracting while peers are exploding. Free cash flow of -$351.8M against $502.3M cash gives ~17 months runway, with dilutive capital raise essentially certain. Debt-to-equity of 0.07 vs. industry 0.24 is the only outperformance — the company is essentially debt-free, eliminating leverage-induced insolvency. P/B of 1.88x is the only valuation anchor. Forward EPS growth of 13.7% (next year) and 10.0% (5-year) are positive directionally but trail industry averages of 42.6% and 23.4% respectively by 67.9% and 57.3% — the most critical comparative weakness for any valuation premium argument.
News Sentiment
Alumis Inc. is navigating one of the most challenging periods in its short history as a public company, following a devastating clinical trial failure that sent shares plummeting 58% in a single day. The experimental drug envudeucitinib — the company's lead candidate — failed to meet its primary endpoint in a mid-stage lupus trial, a setback that wiped out what had been one of biotech's most anticipated pipeline milestones. The trial, known as LUMUS, did offer a glimmer of hope: a subgroup of patients with high-interferon activity showed a meaningful response ('Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise'). The company is now weighing whether to pursue a more targeted late-stage study focused on this subset ('Alumis eyes late-stage lupus study despite trial miss'), though this pivot would require additional capital and years of additional development time. The silver lining for investors lies in psoriasis. Alumis recently released Phase 3 data showing envudeucitinib 'rapidly and durably' cleared skin in psoriasis patients ('Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably...'). Dermatology remains a large, commercially attractive market, and this data keeps an FDA approval pathway alive. For everyday investors, the picture is straightforward: Alumis is a company burning roughly $352 million per year with about 17 months of cash remaining, one failed trial behind it, and one approved therapy still needed to survive. The odds are long, the risk is real, and the timeline is tight.
Risk Assessment
PRIMARY RISK: Cash depletion and dilutive financing. At -$351.8M annual FCF burn against $502.3M cash, the company has ~17 months before requiring a capital raise. Any equity offering at current depressed prices ($6.62) would be severely dilutive to existing shareholders. SECONDARY RISK: Psoriasis approval failure — if the FDA does not approve envudeucitinib, ALMS loses its only remaining near-term commercial catalyst, and the stock could approach book value or below as cash burns down. TERTIARY RISK: Lupus subgroup study failure — 'Alumis eyes late-stage lupus study despite trial miss' represents a resource-intensive second attempt in a smaller patient population; a second miss would be devastating. MITIGATION: The only speculative mitigation is the $502.3M cash buffer and the Phase 3 psoriasis data showing durable skin clearance — if approved, the stock could recover meaningfully. Position size capped at 1.0% of portfolio treats this as a lottery ticket. Stop at $3.50 limits maximum drawdown to ~30% from $5.00 entry.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ALMS a halal stock?
No, Alumis Inc. (ALMS) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ALMS?
Alumis Inc. (ALMS) has a Plutrex AI rating of 28.5/100 with a Strong Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ALMS a good investment?
According to Plutrex AI, ALMS has a Strong Sell rating (28.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ALMS?
US stocks like ALMS can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ALMS?
Plutrex AI identifies the main risks for ALMS by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.